ШВЕБЛЕ Ханс-вильгельм (GB),ДАДЛЕР Томас А. (US),ТЕДФОРД Кларк И. (US),ПЭРЕНТ Джеймс Б. (US),ДЕМОПУЛОС Грегори А. (US)
申请号：
RU2012118506/10
公开号：
RU2012118506A
申请日:
2010.10.15
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. The use of a composition containing an amount of an MASP-2 inhibiting agent effective to inhibit or prevent plaque formation in the vascular system of a subject suffering from or at risk of developing complement-mediated coagulation disorders in the manufacture of a medicament for treating a subject suffering from or at risk of developing complement-mediated coagulation disorders. 2. The use according to claim 1, in which the composition does not increase the susceptibility of a subject to a Neisseria meningitidis meningococcal infection. The use according to claim 1 or 2, wherein the MASP-2 inhibiting agent specifically binds to a polypeptide containing the sequence of SEQ ID NO: 6 with an affinity of at least 10 times greater than when it binds to another antigen in the complement system .four. The use of claim 3, wherein the MASP-2 inhibitor is an anti-MASP-2 antibody or fragment thereof that specifically binds to part of the sequence of SEQ ID NO: 6.5. The use according to claim 4, wherein the anti-MASP-2 antibody or fragment thereof is a monoclonal or recombinant antibody, or is a chimeric, humanized or human antibody, or in which the antibody has reduced effector function. The use according to claim 1, wherein the composition is formulated as a fast-acting dosage form for systemic delivery. The use of claim 1, wherein the complement-mediated coagulation disorder is a complication of the failure of the regulatory complement factor, traumatic injury, or infection. The use of claim 7, wherein the infection is �1. Применение композиции, содержащей количество агента, ингибирующего MASP-2, эффективного для ингибирования или предупреждения образования бляшек в сосудистой системе субъекта, страдающего или предрасположенного к риску развития комплемент-опосредованного нарушения свертывания крови, в производстве лекарственного средства для лечения субъекта, страдающего от или подверженного риску развития комплемент-опосредованного нарушения свертывания крови.2. Приме
